Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
ABILIFY MYCITE KIT is an oral tablet formulation of aripiprazole approved in November 2017 as a digital psychiatric therapeutic combining the antipsychotic agent with ingestible sensor technology for adherence monitoring. The product treats psychiatric indications where treatment compliance is clinically critical, enabling real-time tracking of medication ingestion via a wearable patch and mobile application.
Product is at peak lifecycle stage with no directly measured Part D spending data, suggesting either niche market penetration or data reporting gaps; team size and resource allocation likely stable but dependent on adherence monitoring adoption rates.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ABILIFY MYCITE KIT offers exposure to the convergence of digital health, psychiatric care, and adherence science—a high-growth career area in pharma; however, zero linked job postings suggest either low current hiring velocity or highly specialized recruitment channels, indicating smaller cross-functional team size compared to blockbuster brands.
Worked on ABILIFY MYCITE KIT at Otsuka? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo